Cargando…

What a second booster dose of mRNA COVID-19 vaccines tells us

Detalles Bibliográficos
Autores principales:	Loubet, Paul, Launay, Odile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084693/ https://www.ncbi.nlm.nih.gov/pubmed/35550263 http://dx.doi.org/10.1016/S1473-3099(22)00282-1

Ejemplares similares

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
por: Oosting, Sjoukje F, et al.
Publicado: (2022)

Impact of methotrexate on first-dose COVID-19 mRNA vaccination
por: Connolly, Caoilfhionn M, et al.
Publicado: (2021)

What mRNA Abundances Can Tell us about Metabolism
por: Hoppe, Andreas
Publicado: (2012)

What does the success of mRNA vaccines tell us about the future of biological therapeutics?
por: Karikó, Katalin, et al.
Publicado: (2021)

Unintended pregnancy and abortion: what does it tell us about reproductive health and autonomy?
por: Kantorová, Vladimíra
Publicado: (2020)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Protein-based vaccine as the booster dose for adults: evidence and beyond
por: Shang, Lianhan, et al.
Publicado: (2022)

COVID-19 mRNA vaccination and myocarditis or pericarditis
por: Husby, Anders, et al.
Publicado: (2022)

Safety of mRNA COVID-19 vaccines during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2022)

Recovery from mRNA COVID-19 vaccine-related myocarditis
por: Ammirati, Enrico, et al.
Publicado: (2022)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

Number needed to vaccinate for COVID-19 booster doses: a valuable metric to inform vaccination strategies
por: Feng, Shuo, et al.
Publicado: (2023)

Adult-onset Still's disease after mRNA COVID-19 vaccine
por: Magliulo, Daniel, et al.
Publicado: (2021)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: Possible immune reconstitution by mRNA vaccination
por: Ota, Mitsuhito
Publicado: (2022)

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
por: Frey, Sarah, et al.
Publicado: (2022)

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
Publicado: (2022)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
por: Heymans, Stephane, et al.
Publicado: (2021)

Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19
por: Richardson, Christopher D
Publicado: (2022)

CS-2034 mRNA vaccine: a new option for COVID-19 infection?
por: Zhang, Ruiqi, et al.
Publicado: (2023)

Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
por: Hung, Ivan F N, et al.
Publicado: (2021)

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

Updated report of COVID-19 vaccine safety monitoring in Japan: booster doses for Omicron variants and vaccinations for infants and young children
por: Yamaguchi, Toshihiro, et al.
Publicado: (2023)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Why promoting a COVID-19 vaccine booster dose?
por: Loubet, Paul, et al.
Publicado: (2021)

Safety of COVID-19 booster dose: is the juice worth the squeeze?
por: Madhi, Shabir A, et al.
Publicado: (2023)

Mobile phone–based interventions for mental health show promise of effectiveness, but what does the evidence tell us about what needs to come next?
por: Jacobson, Nicholas C., et al.
Publicado: (2022)

mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks, and Coverage
por: Nashwan, Abdulqadir J., et al.
Publicado: (2022)

Abstract #1403045: Thyroiditis Post COVID-19 mRNA Booster Dose Vaccination
por: Seow, Cherng Jye
Publicado: (2023)

COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
por: Krantz, Matthew S, et al.
Publicado: (2022)

Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic
por: Morris, Van K., et al.
Publicado: (2022)

Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
por: Leclerc, Mathieu, et al.
Publicado: (2022)

Tales the double helix tells
por: Jobling, Mark A
Publicado: (2010)

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
por: Scoccianti, Silvia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n5ltepurb6f9sbgqkt54ddq0lf